Tarsus Pharmaceuticals, Inc.TARSNASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank43
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-22.31M
↑ 41% vs avg
Percentile
P43
Within normal range
Streak
2 yr
Consecutive growthExpanding
Average
$-37.86M
Historical baseline
PeriodValueYoY Change
TTM$-22.31M+73.6%
2024$-84.59M+31.2%
2023$-123.00M-148.3%
2022$-49.54M-1666.6%
2021$3.16M+114.6%
2020$-21.59M-461.2%
2019$-3.85M-223.4%
2018$-1.19M-